“[PDAC] has a poor prognosis, with a 5-year survival of <10% because of diffuse symptoms leading to late-stage diagnosis. That survival could increase significantly if localized tumors could be detected early,” Dr Mellby and colleagues posited. Read more . . .
A liquid biopsy that uses a serum biomarker signature can detect early-stage, localized pancreatic ductal adenocarcinoma (PDAC), according to results from a recent study by Linda D. Mellby, PhD, Development Director, Immunovia AB, Lund, Sweden, and colleagues (J Clin Oncol. 2018;36:2887-2894).